NXTC compared with LPCN: revenue, margins and what each company keeps, and the suppliers and customers both name

NXTCNextCure, Inc.

Mkt capRevenueRevenue

LPCNLipocine Inc.

Mkt capRevenueRevenue

Compare

NXTCNextCure, Inc.

LPCNLipocine Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only NXTC 7

—LigaChem Biosciences, Inc., formerly known as LegoChem Biosciences, Inc ("LigaChem")unlistedsupplier

—Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical, Ltd. or hereinafter "Zaiming")unlistedsupplier

—WuXi XDCunlistedsupplier

—Yale University ("Yale")unlistedsupplier

3 more · NXTC chain ›

Shared 0

No disclosed counterparties: LPCN.

Only LPCN 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

NXTCNextCure, Inc.

5.10▼−0.39%· post 5.10

Mkt cap$24.4MRevenue—Revenue—

LPCNLipocine Inc.

1.58▲+3.56%· post 1.55

ClosedNov 6 '26

Mkt cap$17.4MRevenue$2MQ3 FY26Revenue$2MFY25

Compare

ClosedNov 6 '26

NXTCNextCure, Inc.

LPCNLipocine Inc.

5.10▼−0.39%post 5.10

Price

1.58▲+3.56%post 1.55

$24.4M

Mkt cap

$17.4M

—

Revenue

$2MQ3 FY26

—

Revenue

$2MFY25

NXTC5.10▼−0.39%vsLPCN1.58▲+3.56%ClosedNov 6 '26